Skip to content
pharmaceutical hero image
pharmaceutical hero image


We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.

We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.

News & insights

A droplet of liquid failing into pharmaceutical test tubes

Publications: 09 JUNE 2021

A&O hosts webinar on drug formulations in life sciences transactions

On Tuesday 25 May 2021, Allen & Overy IP associate Tine Carmeliet chaired a presentation with IP partner Keren Livneh and IP associate Megan McMellon and M&A associate Zara Sproul on “Drug…

Read more
Vials of medication during production

Publications: 15 DECEMBER 2020

Healthcare accent is on smaller deals

Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years. 

Read more

Blog Post: 09 JUNE 2020

Covid-19 coronavirus: French High Health Authority publishes position on the use of rapid serological tests

Further to publishing evaluation criteria for serological tests for antibodies against SARS-CoV-2 (available here), the French High Health Authority (HAS) published on 18 May 2020 its opinion on the…

Read more

Blog Post: 03 JUNE 2020

Start of French medical cannabis pilot programme postponed to January 2021

Today, the French Medicines Agency (ANSM) and the Health Ministry published an update on the continuance of the work of the Scientific Committee (CST) with respect to the French medical cannabis pilot…

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2021

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.